<DOC>
	<DOCNO>NCT00701649</DOCNO>
	<brief_summary>CYT006-AngQb vaccine induces B-cell mediate immune response characterize generation specific antibody ( IgG IgM ) Angiotensin II . The vaccine administer subcutaneous injection . The objective study : - To evaluate safety tolerability 5 s.c. injection 300µg CYT006-AngQb Alhydrogel™ patient mild moderate essential hypertension ( hypertension Grade I II ) . - To assess pharmacodynamic effect , i.e . anti-Ang II immune response renin- angiotensin system ( RAS ) biomarkers . - To explore effect blood pressure use ABPM .</brief_summary>
	<brief_title>Study Evaluate Safety Tolerability , Pharmacodynamic Effects Exploratory Efficacy Vaccine Against Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Patients mild moderate essential hypertension ( Grade I Grade II ) mean sit office SBP =140179 mmHg and/or mean sit office DBP = 90109 mmHg 2 consecutive visit ( screen V1 ) . Daytime blood pressure threshold definition hypertension screen ABPM measurement ( SBP &gt; 135 mmHg ) . Patients without current antihypertensive therapy . Patients antihypertensive therapy , stop . 18 69 year age . Male patient , female patient without childbearing potential . Patients `` high add risk '' accord 2007 Guidelines Management Arterial Hypertension ( Journal Hypertension , 2007 , 25:11051187 ) , i.e . : grade III hypertension ( mean sit office SBP ≥180mmHg and/or mean sit DBP≥110mmHg ) history presence establish cardiovascular renal disease : Ischemic stroke , cerebral hemorrhage , transient ischemic attack Myocardial infarction , angina pectoris , coronary revascularization , heart failure Peripheral artery disease Diabetic nephropathy Known autoimmune disease . Severe allergy . Pregnancy breastfeed . Women childbearing age surgically sterilize . Patients history current positive test HIV infection , AIDS , immunosuppressive disorder ; hepatitis B C. Current diagnosis history malignancy . Presence suspicious lymphadenopathy splenomegaly physical examination . Drug alcohol abuse within past 2 year . Presence history relevant cardiovascular , renal , hepatic , pulmonary , endocrine , autoimmune , neurological psychiatric disease judge investigator . Any current past disease condition ( physical mental ) would , opinion investigator , interfere study procedure interpretation study data ( e.g . worker night shift ) . Previous participation clinical trial Qb base vaccine . Use investigational drug within 3 month enrolment , plan use whole study period . Possible dependency patient sponsor and/or investigator . Planned active immunization 2 week 2 week study medication vaccination . Donation loss &gt; =400 mL blood within 8 week prior dose major surgery within past 2 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>mild essential hypertension</keyword>
	<keyword>moderate essential hypertension</keyword>
</DOC>